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Abstract Randomized controlled trials always report the
dose assessed and usually include a measure of adher-
ence. By comparison, observational studies assessing
medication safety often fail to report the dose used and
rarely report any measure of adherence to therapy. This
limits the ability to control for differences in doses used
when undertaking meta-analyses. Non-adherence with
therapy is common in the practice setting and varies
across countries and settings. Inter-country differences in
the registration of medicines may also result in different
product strengths being available in different countries.
These two factors combined means that observational
studies undertaken for the same medicine in different
settings may be assessing the same medicine but in cir-
cumstances where quite different dosages are used. Given
that many adverse drug effects are dose dependent, dif-
ferences in dosages used could be a factor explaining
differences in risk estimates observed across studies. We
argue that dose intensity, which can be defined as a
product of the dose prescribed and adherence to the dose
prescribed over the course of treatment, should be rou-
tinely reported in observational studies of medication
safety. We illustrate the issue with the example of dabi-
gatran. The randomized controlled trial evidence under-
pinning dabigatran’s marketing authorization resulted in
uncertainty about the appropriate dose for efficacy versus
safety. As a result, different dosages of dabigatran were
registered in the USA and Europe. The USA registered
the 150- and 75-mg dabigatran products, while the 150-
and 110-mg dabigatran products were registered in Eur-
ope. Among five observational studies subsequently
undertaken to resolve the safety question concerning
dabigatran and risk of bleeding, only one stratified results
by dose. None of the US studies stratified results by the
75-mg dabigatran dose, despite this dose not being
assessed in the original trial. None of the five studies
reported adherence measures, despite three separate
observational studies finding between 25 and 40 % of
patients were non-adherent to dabigatran. The STROBE
and RECORD statements should consider adding the
requirement for reporting measures of dose intensity and
its component products to improve observational study
reports.
Key Points
Medication dose intensity, which provides a measure
of the dose given, is a function of the dose prescribed
and adherence to dose prescribed within a given
period of time.
A difference in dose intensity is one factor that can
contribute to differences in risk estimates of
medication safety across studies.
Medication dose intensity, including its component
parts, should be routinely reported in observational
studies assessing medication safety.
Adjusting for dose intensity will enable valid
comparisons of risk estimates across studies.
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1 Introduction
1.1 Reporting Medication Doses and Adherence
Measures in Clinical and Observational Studies
Randomized controlled trials assessing the safety and
efficacy of new medicines always report the doses studied
and generally include a measure of patient adherence with
therapy during the study period. The adherence measure
can be considered a process measure for the trial that
enables assessment of the extent to which the intended
dosage was administered. Knowledge of the extent of
adherence by participants in the trial is needed to minimize
the risk of bias that can arise when adherence rates differ
significantly between patients in the different arms of the
trial.
Similarly to randomized controlled trials, observational
studies may also be subject to bias due to non-adherence
with therapy. This is recognized in guidelines for reporting
observational studies, including the US FDA guideline,
‘Best Practices for Conducting and Reporting Pharma-
coepidemiologic Studies using Electronic Health Care
Data’ [1]. This guideline highlights the importance of
identifying gaps in therapy and determining when gaps are
long enough to be a true interruption to therapy. The
guideline also highlights the need to correctly ascertain
dose from electronic healthcare data, and indicates the need
to clearly define how this is achieved. The ‘Strengthening
reporting of observational studies in epidemiology’
(STROBE) statement [2] also highlights the need to clearly
define exposure ascertainment. The FDA guideline and
STROBE statement do not include any statement about the
need for reporting the doses used or adherence to the
medicines. Research undertaken to develop the ‘Reporting
of studies conducted using observational routinely-col-
lected data’ (RECORD) statement also does not highlight
the issue of reporting the dose used or adherence to the
medicine under study [3]. One of the limitations of not
reporting the dose used or adherence to the medicines is the
lack of ability to control for drug dose in subsequent meta-
analyses and systematic reviews [4].
1.2 Dose Intensity as a Measure for Reporting Dose
and Adherence
Dose intensity is a measure commonly used in oncology to
enable comparisons of chemotherapy regimens [5]. Dose
intensity is measured as the amount of drug given within a
specified period of time [5]. A second measure, known as
relative dose intensity is a measure of the amount of drug
delivered as a ratio of the amount of drug planned to be
administered [6]. By adapting these measures to
observational studies of medicine use, dose intensity can be
described as the product of the dosage prescribed and the
adherence with the dosage prescribed during treatment
periods. In general, this should be reported as an average
dosage per day. In drug safety research, dose intensity may
influence the strength of association with the outcome or
adverse drug effect under assessment because the majority
of adverse drug effects are dose dependent [7]. Thus,
studies involving subjects where the average dose intensity
is low may be less likely to show an association than
studies where the average dose intensity is high [4].
1.3 The Influence of Medication Non-Adherence
on Outcomes
There is a significant body of literature showing that there
are high levels of non-adherence with medicines in many
populations [8–10]. Non-adherence with a medicine can be
accidental and minimal, for example, the omission of a
single dose, or can range to complete non-adherence, such
as when patients do not take any of the prescribed medi-
cine. Within a population, the full spectrum of non-ad-
herence from minimal to full is likely to exist. Hyper-
adherence is another form of non-adherence, where
patients take more than the prescribed dose. The impact of
non-adherence with medicines on clinical outcomes may
vary by the amount of non-adherence and whether it is
predominantly omission or addition of therapy. A meta-
analysis of the effect of adherence with any medical
treatment on health outcomes demonstrated a 26 % overall
risk difference in outcomes between high and low adher-
ence [odds ratio (OR 2.88, 95 % confidence interval (CI)
2.23–3.73] [11]. When limited to studies on medication
use, the risk difference was 21 %. The analysis showed the
effect was more apparent for chronic diseases where the
risk difference was 31 %; however, a risk difference of
20 % was apparent for acute conditions [11]. For many
medicines used for preventive purposes, such as medicines
used to treat diabetes, hypertension, and hyperlipidemia,
long-term adherence and persistence are factors likely to
affect outcomes. However, for other conditions, even small
levels of non-adherence, or small interruptions to therapy,
can reduce medication effectiveness or cause harms or
unintended consequences. Examples include the oral anti-
coagulants [12, 13], medicines for immunosuppression in
transplant recipients [14], oral contraceptives [15], and
medicines for treatment of human immunodeficiency virus
[16, 17].
The majority of pharmacoepidemiological studies
assessing adverse drug effects do not report any adherence
measures and many neither stratify results by dosage nor
report the mean dosages used. We argue that it is time to
consider including the need to report measures of dose
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intensity in studies, as well as articulate this requirement in
guidelines for reporting pharmacoepidemiological studies.
The overall measure should be reported, as should its
component parts. Wherever possible, stratification by dose
prescribed should be reported; however, in circumstances
where this is not appropriate, such as where dose is titrated
to a surrogate endpoint, mean dose should be reported. The
distribution of adherence scores should be also be reported.
To illustrate the issue, we review the reporting of
adherence or dose intensity in the observational studies that
have assessed adherence with and safety of the oral anti-
coagulant dabigatran. We chose an oral anticoagulant as
the case study because non-adherence with anticoagulants
is associated with increased risk of poor outcomes [18], and
there are differences in the dose formulations approved
across countries [19]. We compare the outcomes from the
observational studies with knowledge generated from the
randomized controlled trial that underpinned dabigatran’s
marketing authorization.
2 The Dabigatran Example
2.1 The Randomized Controlled Trial Evidence
for Dabigatran Safety and Efficacy Compared
with Warfarin
Dabigatran is a novel oral anticoagulant that directly
inhibits thrombin. The initial randomized controlled trial
evidence that supported dabigatran’s market authorization
was the RE-LY trial, a multi-center, non-inferiority, ran-
domized controlled trial assessing the efficacy and safety of
dabigatran in comparison with warfarin [20]. Two different
doses of dabigatran were trialed, 110 and 150 mg, while
warfarin was dose adjusted based on results of prothrombin
time. Collectively, the study results demonstrated dabiga-
tran was non-inferior to warfarin at doses of 110 mg
[hazard ratio (HR) 0.90, 95 % CI 0.74–1.10] and superior
to warfarin at doses of 150 mg (HR 0.65, 95 % CI
0.52–0.81) for the primary endpoint of stroke or systemic
embolism. With regards to adverse drug effects, major
bleeding risk with dabigatran at a dose of 150 mg was
similar to that for warfarin (HR 0.93, 95 % CI 0.81–1.07),
while there was a lower risk of major bleeding for dabi-
gatran at the 110 mg dose than for warfarin (HR 0.80,
95 % CI 0.69–0.93) [20]. These results are suggestive of a
dose-response effect to the adverse drug effect of major
bleeding. This dose-response effect was also observed
when limiting the analysis of the adverse drug effect to
gastrointestinal bleeding. An equivalent risk of gastroin-
testinal bleeding was observed between dabigatran 110 mg
and warfarin (HR 1.10, 95 % CI 0.86–1.41), and a higher
risk of gastrointestinal bleeding was observed with
dabigatran 150 mg compared with warfarin (HR 1.36,
95 % CI 1.09–1.70) [20].
2.1.1 The Randomized Controlled Trial Evidence
and the Effect of Adherence
The potential impact that adherence could have on the risk
of major bleeding became apparent when the results of the
randomized controlled trial were stratified by time in
therapeutic range [21]. Time in therapeutic range was
measured for the warfarin arm of the trial [21]. A number
of factors can influence time in therapeutic range, including
adherence, changes in dietary vitamin K intake, inter-cur-
rent illness, and co-administration of interacting medicines.
The results of the trial were stratified by the quartiles
observed in the trial for time in therapeutic range:\57.1,
57.1–65.5, 65.5–72.6, and[76.2 % [21]. For the warfarin
patients with time in therapeutic range[72.6 % (a poten-
tial measure of high adherence), the randomized controlled
trial results showed that dabigatran 150 mg was non-infe-
rior to warfarin with regards to stroke or systemic embo-
lism (i.e., the superiority disadvantage disappeared) (HR
0.95, 95 % CI 0.61–1.48). The reduced risk of major
bleeding that had been observed at the 110-mg dose of
dabigatran for the collective population was no longer
evident compared with the warfarin population that had
high periods of time in therapeutic range ([72.6 %) (HR
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Fig. 1 Risk of gastrointestinal bleed for dabigatran 150 and 110 mg
versus warfarin. CI confidence interval, HR hazard ratio (Source:
Wallentin et al. 2010) [21]
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gastrointestinal bleeding by time in therapeutic range, the
trend in dose response was also apparent (see Fig. 1). One
adverse drug effect that remained reduced compared with
the warfarin population that had high periods of time in
therapeutic range ([72.6 %) was intracranial bleed, the
risk of which was reduced with dabigatran 150 mg com-
pared with warfarin (HR 0.39, 95 % CI 0.18–1.54) [21].
2.2 Adherence Differences and the Translation
of the Trial Results into Practice
At the time of marketing, concerns were raised about how
the RE-LY trial results would translate into practice, as
poor adherence to therapy with either dabigatran or war-
farin could result in the loss of any therapeutic advantage
that one product had over the other [22].
Dabigatran has a dosage schedule of twice daily com-
pared with warfarin’s once-daily dosing schedule. Because
of the shorter half-life of dabigatran, poor adherence to the
twice-daily dabigatran dosage schedule may mitigate any
efficacy advantage over warfarin. In addition, a claimed
advantage for dabigatran was the lack of a need for mon-
itoring of therapeutic drug levels, a requirement for war-
farin that could be a barrier to either initiation or
persistence with therapy in some people. However, the
requirement for regular monitoring could also provide an
opportunity to support adherence to warfarin therapy, and
hence the lack of monitoring with dabigatran may result in
poorer adherence to dabigatran therapy. Again, if poorer
adherence was observed with dabigatran, any efficacy
gains would be lost.
Further, the RE-LY trial results demonstrated that the
proportion of warfarin patients with time in therapeutic
range varied by country, with the mean time in therapeutic
range for warfarin as low as 44 % in some countries and up
to 77 % in others [21]. Countries where patients on war-
farin were in therapeutic range for the majority of time may
not realize any therapeutic advantage of dabigatran.
Additionally, the trial results demonstrated that patient
experience of warfarin use was also a factor in maintaining
therapeutic range, with patients naı¨ve to warfarin prior to
the study having less time in therapeutic range than patients
who had used warfarin previously [21]. Thus, uptake of
dabigatran in the warfarin-naı¨ve population compared with
the warfarin-experienced population may not yield the
same therapeutic advantage.
One additional complicating factor was the response of
the USA and European regulators to the trial evidence [19].
Dabigatran was approved at the trial doses of both 110 and
150 mg in Europe; however, in the USA, it was concluded
that dabigatran 150 mg was superior to warfarin in all
subgroups of patients, thus, the 110-mg dose was not
approved [23]. Dabigatran is excreted predominantly via
the kidneys, thus, lower dosages are required in patients
with renal impairment; for this reason, a dosage of 75 mg
was approved in the USA [23]. The 75-mg dose approved
in the USA had not been assessed in the clinical trial, thus
the clinical efficacy and safety at the 75-mg dose was
unknown.
Given the uncertainty about how the clinical trial evi-
dence would translate into practice and the significant
potential for patient adherence to influence the results,
observational research has focused on assessing adherence
to dabigatran or investigating the safety and effectiveness
of dabigatran in practice. However, as we highlight in the
next section, observational studies of dabigatran’s effec-
tiveness and safety do not report adherence levels and do
not always report dosages used, all of which have impli-
cations for the interpretation of the safety and effectiveness
results arising from the observational evidence.
2.3 The Observational Evidence
2.3.1 The Observational Evidence of Adherence
with Dabigatran
We identified three retrospective cohort studies that
assessed adherence to dabigatran [24–26]. None of these
studies included a warfarin arm. Two of the studies
demonstrated high rates of adherence to dabigatran, with
more than 70 % of patients considered adherent with
therapy [25, 26] (Table 1). Consistent with the clinical trial
evidence that showed the mean time in therapeutic range
for warfarin was as low as 44 % in some countries and
varied up to 77 % in others [21], differences in dabigatran
adherence rates by site were also evident from the obser-
vational evidence [27]. A US study involving 67 sites that
had at least 20 patients taking dabigatran reported variation
in adherence by site ranging from 42 to 93 % [27]. Median
adherence performance by site was 74 %. After adjusting
for site and patient characteristics, the variation was still
found to be present [27].
Two of the observational studies on adherence with
dabigatran reported the proportion of the population
receiving the 150-mg dose [25, 26]. The rate was 61 %
receiving dabigatran 150 mg in the study from the Euro-
pean country, where both the 110- and the 150-mg doses
are available, and higher, at 83.6 % receiving dabigatran
150 mg in the US study, where the 150-mg dosage is
recommended for the majority of patients. The higher level
of use of dabigatran 150 mg in the USA is consistent with
registry data from the USA that found 87 % of dosages of
dabigatran were for the 150-mg product [28]. Similarly, the
lower level of use of the 150-mg strength in the European
study may be reflective of the use of lower doses in
countries where the 110-mg strength is available. In
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Turkey, only 45 % of dabigatran use was for the higher
strength [29], and a European survey reported 61 % of
dabigatran use in adults was at the 150-mg strength [30].
2.3.2 The Observational Evidence of Dabigatran Safety
and Effectiveness Compared with Warfarin
We located five observational studies that had assessed risk
of gastrointestinal bleeding with dabigatran compared with
warfarin in patients who were naı¨ve to both therapies; two
of these also reported outcomes for ischemic stroke [31–
35]. Uncertainty in the translation of the RE-LY trial to the
real-world setting was the rationale underpinning the
studies. All of the studies reported outcomes for popula-
tions with atrial fibrillation, and these results were extrac-
ted for comparison (see Table 2). Four of the studies were
based in the USA and one was from Denmark. All studies
were retrospective observational studies using electronic
health data, and all studies had a new user design. All
studies used propensity scores to provide balance across
study arms, with two studies using inverse probability of
treatment weights (IPTW) and the remaining three studies
using matched propensity score designs. All studies pro-
vided data to demonstrate how propensity weighting or
matching improved covariate balance.
None of the studies reported an average adherence
measure or the distribution of adherence scores for par-
ticipants, despite the observational evidence from separate
studies showing between 25 and 40 % could be non-ad-
herent with dabigatran. None of the studies reported time in
therapeutic range for subjects receiving warfarin. Only the
Danish study stratified results by the dabigatran strength
used. None of the US studies reported the proportion of
participants receiving the 75-mg dose of dabigatran, nor
stratified results by this dose, despite this dose not having
been assessed in the clinical trial.
With regards to the outcome of gastrointestinal bleed,
two studies reported a significant increased risk of gas-
trointestinal bleed with dabigatran compared with warfarin,
while two studies showed no difference in risk between the
two medicines (Table 2). The Danish study, which strati-
fied results by dose, found a lower risk of gastrointestinal
bleeding with dabigatran 110 mg than with warfarin and no
increased risk with dabigatran 150 mg compared with
warfarin (Table 2). With regards to the outcome of
ischemic stroke, the Danish study reported no increased
effectiveness at dabigatran 150 mg compared with warfarin
(HR 1.18, 95 % CI 0.85–1.64) and borderline effectiveness
at the 110-mg dose (HR 0.73, 95 % CI 0.53–1) [34]. The
mean age of dabigatran users in the Danish study was 67.4
years for the 150-mg dose and 74.7 years for the 110-mg
dose. The US study that assessed ischemic stroke found no
difference in risk between dabigatran and warfarin users
(HR 0.91, 95 % CI 0.81–1.02) [35].
We cannot ascertain the impact of dose intensity, either
due to patient non-adherence or due to differential doses
prescribed, because these data were not reported in the
published studies. However, if there were significant
numbers of the population with poor adherence, this would
create a bias to the null, and the observational evidence
assessing adherence suggests at least a proportion of the
population were non-adherent. Similarly, if a significant
proportion of the population were receiving the 75-mg
dose, this may also create a bias to the null. In the two US
studies where increased risk of gastrointestinal bleeding
was observed, the dabigatran cohort had higher mean ages
than in the US studies where no increased risk was
observed (Fig. 2). Given the lack of a 110-mg dose in the
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USA and the higher proportion of use of dabigatran
150 mg in the USA than in Europe, it is possible that the
differential effect observed in the US studies is partially
attributable to a dose-intensity effect. In the USA, 83 % of
people aged C80 years are prescribed dabigatran 150 mg
[28]; in comparison, only 61 % of the elderly in Europe are
prescribed the 150-mg dose [34].
3 The Implications for Medication Safety
Research
In this example, we have shown that despite prior knowl-
edge that the dosage of dabigatran used had a differential
effect on both safety and efficacy outcomes, none of the
published US studies stratified results by the 75-mg dose, a
dose that had not been trialed. Only the Danish study
stratified results by dosage used. Further, despite prior
concerns that patient adherence would be a factor con-
tributing to whether any potential safety or efficacy gains
with dabigatran were realized in practice, none of the
studies assessing outcomes reported an adherence measure.
There are potential consequences of not reporting dose
intensity with observational studies, particularly as the
same strength medicines are not necessarily available in all
countries. Meta-analyses of medication safety effects
without stratification by dose could be biased by the
inclusion of studies where dosages differ substantially
across studies [4]. For the dabigatran example, pooling data
from all studies would provide a result dominated by the
US studies, where a higher dose of dabigatran is routinely
used compared with Australia and countries in Europe.
This may result in over-estimated risks for countries out-
side the USA where lower doses are more commonly used.
International networks to assess drug safety are developing
Table 2 Observational studies assessing gastrointestinal bleeding risk with dabigatran compared with warfarin
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Fig. 2 Risk of gastrointestinal bleeding with dabigatran compared to
warfarin users and mean age of study cohort. CI confidence interval,
HR hazard ratio
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[36, 37], and it will be increasingly important to report
measures of dose and dose intensity so that valid com-
parisons within and across countries can be made.
Another example of the limitations of not reporting dose
in observational studies is found in the observational
studies assessing cardiovascular risk with non-steroidal
anti-inflammatory agents. Rofecoxib was approved in the
USA in a 50-mg formulation; however, countries such as
Australia did not register this dose, only registering the
25-mg product. At least 34 observational studies have been
undertaken assessing cardiovascular risk from rofecoxib;
however, the majority have not reported the dose used [38].
Thus, less than half were able to be pooled in analyses to
assess dose response. The dose-response analysis revealed
a dose-response effect, with a doubling in risk of adverse
cardiovascular outcomes [risk ratio (RR) 2.17, 95 % CI
1.59–2.97] for doses above 25 mg per day compared with a
37 % increased risk for doses of 25 mg per day or less (RR
1.37, 95 % CI 1.20–1.57) [38]. Of the 177 observational
studies reported in a meta-analysis assessing cardiovascular
risk with non-steroidal anti-inflammatory agents, only one-
third were able to be analysed for dose-response effects
[38].
4 Conclusion
The lack of reporting of dose intensity in observational
studies of medication safety is a lost opportunity for
improving medication safety research and limits the ability
to control for differential doses when undertaking meta-
analyses and systematic reviews. This issue could be easily
addressed by requirements to include reporting of dose
intensity in guidelines for observational study reporting. In
a similar way to the requirement to report the results of
propensity adjustment on patient characteristics, which all
the studies reviewed in this paper did, the guidelines for
reporting medication safety studies from electronic health
data should include a requirement to report measures of
dose intensity and its component parts. Ideally, the mea-
sures would include dose stratification or mean dose, where
dose stratification is not possible, and a measure of
adherence and the distribution of adherence scores across
the study population. As guidelines for reporting results of
observational studies from electronic health data are
developed, we argue that consideration should be given to
including a requirement for reporting dose intensity.
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